<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03004001</url>
  </required_header>
  <id_info>
    <org_study_id>VA16-029</org_study_id>
    <nct_id>NCT03004001</nct_id>
  </id_info>
  <brief_title>Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome</brief_title>
  <official_title>Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gloria Vega</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aventis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dallas VA Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study purpose is to determine the hypolipidemic effect of Alirocumab co-administered with
      atorvastatin on levels of triglyceride-rich lipoproteins and LDL compared to monotherapy with
      atorvastatin in patients with dyslipidemia secondary to nephrotic syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is randomized (1:1 alirocumab to placebo), double-blinded, placebo-controlled with
      a cross-over design. The trial will last 10 months and includes a 10 week washout period
      between study phases.Twenty adult subjects with dyslipidemia secondary to nephrotic syndrome
      and treated with atorvastatin will be recruited. Alirocumab or placebo will be
      co-administered biweekly. Safety, efficacy chemistries, vital signs, anthropometry and
      monitoring for adverse events also will done at each visit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Levels of plasma lipoproteins</measure>
    <time_frame>up to 10 months</time_frame>
    <description>ion mobility lipoprotein analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels of PCSK9</measure>
    <time_frame>up to 10 months</time_frame>
    <description>immunoassay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride-rich lipoproteins (Remnants)</measure>
    <time_frame>up to 10 months</time_frame>
    <description>immunoassay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipidomics</measure>
    <time_frame>up to 10 months</time_frame>
    <description>mass spectroscopy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Nephrotic Syndrome</condition>
  <arm_group>
    <arm_group_label>Alirocumab and atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alirocumab 150 mg bi-weekly and atorvastatin 20 mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alirocumab placebo and atorvastatin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Alirocumab placebo biweekly and atorvastatin 20 mg/d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alirocumab</intervention_name>
    <description>150 mg biweekly</description>
    <arm_group_label>Alirocumab and atorvastatin</arm_group_label>
    <other_name>Praluent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alirocumab placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Alirocumab placebo and atorvastatin</arm_group_label>
    <other_name>Praluent placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>20 mg/day</description>
    <arm_group_label>Alirocumab and atorvastatin</arm_group_label>
    <arm_group_label>Alirocumab placebo and atorvastatin</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Nephrotic Syndrome (NS) (FSGS, IMN or NS and type 2 DM)

          -  atorvastatin

          -  LDL C &gt;= 70 mg/dl or non-HDL C &gt;= 100 mg/dl

          -  Plasma trigycerides &lt; 800 mg/dl.

          -  Highly effective methods of contraception for pre-menopausal women

          -  Post-menopausal women must be amenorrheic for at least 12 months.

        Exclusion Criteria:

          -  homozygous FH

          -  Fibrates within 6 weeks of screening visit

          -  Uncontrolled hypothyroidism

          -  Known history of hemorrhagic stroke

          -  Known history of loss of function of PCSK9

          -  use of systemic corticosteroids unless used as replacement therapy for
             pituitary/adrenal disease with a stable regimen for at least 6 weeks of randomization

          -  Previous treatment with at least a single dose of alirocumab or any other anti-PCSK9
             monoclonal antibody

          -  Other conditions or situations per protocol

          -  Laboratory findings or contraindications to background therapies

          -  Warnings/precautions of use (when appropriate) as displayed in the respective national
             product labeling

          -  Any currently known contra-indication to study drug, pregnancy or breastfeeding of
             infants.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gloria L Vega, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dallas VAMC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yin Oo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dallas VA Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Concepcion, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dallas VA Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Nguyen, BS</last_name>
    <phone>214 8570323</phone>
    <email>Peter.Nguyen6@va.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sami Alaraj, BS</last_name>
    <phone>214 8570323</phone>
    <email>Sami.Alaraj@va.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>DallasVAMC</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjai Sabu</last_name>
      <phone>214-857-0323</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Vega GL, Grundy SM. Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism. Kidney Int. 1988 Jun;33(6):1160-8.</citation>
    <PMID>3165483</PMID>
  </reference>
  <reference>
    <citation>Toto RD, Grundy SM, Vega GL. Pravastatin treatment of very low density, intermediate density and low density lipoproteins in hypercholesterolemia and combined hyperlipidemia secondary to the nephrotic syndrome. Am J Nephrol. 2000 Jan-Feb;20(1):12-7.</citation>
    <PMID>10644862</PMID>
  </reference>
  <reference>
    <citation>Vega GL, Toto RD, Grundy SM. Metabolism of low density lipoproteins in nephrotic dyslipidemia: comparison of hypercholesterolemia alone and combined hyperlipidemia. Kidney Int. 1995 Feb;47(2):579-86.</citation>
    <PMID>7723244</PMID>
  </reference>
  <reference>
    <citation>Jin K, Park BS, Kim YW, Vaziri ND. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study. Am J Kidney Dis. 2014 Apr;63(4):584-9. doi: 10.1053/j.ajkd.2013.10.042. Epub 2013 Dec 4.</citation>
    <PMID>24315769</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2016</study_first_submitted>
  <study_first_submitted_qc>December 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2016</study_first_posted>
  <last_update_submitted>March 10, 2017</last_update_submitted>
  <last_update_submitted_qc>March 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Dallas VA Medical Center</investigator_affiliation>
    <investigator_full_name>Gloria Vega</investigator_full_name>
    <investigator_title>Principal Investigator at Dallas VA Medical Center</investigator_title>
  </responsible_party>
  <keyword>Severe proteinuria</keyword>
  <keyword>Dyslipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

